Fitch Rating, like S&P, affirms Grifols' BB- corporate (CFR) and assigns BB+ to senior secured debt and B+ to senior unsecured debt Grifols’ latest ratings highlight its continued solid market position, robust business model, cash-generation capacity, and the significant added value of the Biotest transaction Grifols expects its leverage ratio to fall below 3.5x in 2024.
- Fitch Rating, like S&P, affirms Grifols' BB- corporate (CFR) and assigns BB+ to senior secured debt and B+ to senior unsecured debt
- Grifols’ latest ratings highlight its continued solid market position, robust business model, cash-generation capacity, and the significant added value of the Biotest transaction
- Grifols expects its leverage ratio to fall below 3.5x in 2024
Barcelona, September 27, 2021.- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS) earned its first credit rating from Fitch Rating, which joins other agencies like S&P and Moody's in evaluating the company’s issue of EUR 2,000 million in senior unsecured notes with a 7-year maturity, launched to finance the Biotest transaction.
Specifically, Fitch Rating ranked Grifols' corporate family rating (CFR) BB- with an outlook of “stable,” and assigns BB+ and B+ to senior secured debt and to senior unsecured debt, respectively.
This rating is in line with S&P’s rating, which affirmed Grifols’ BB- CFR with a negative outlook and BB and B for its senior secured and senior unsecured senior debt, respectively. This credit rating is one notch above Moody’s corporate credit rating and two notches above senior secured and senior unsecured debt.
These analyses still reflect Grifols’ solid market position, robust vertically integrated business model and solid fundamentals, which will continue to generate important operating cash flows and help the company reduce its leverage.
For Alfredo Arroyo, Grifols CFO , “We are pleased with the market’s vote of confidence ahead of the Biotest transaction, which represents a unique and transformational opportunity to significantly reinforce our market position, accelerating and expanding our product portfolio, and in turn, boosting our growth and profitability. Based on our forecasts, we will achieve over EUR 7 billion in combined revenues, more than EUR 2 billion in EBITDA and a more than 30% EBITDA margin. All of this will contribute to swiftly and progressively decrease our leverage ratio below 3.5x by 2024.”
Add new comment